Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEMarc Humbert, K. Surrey, Richard Beasley et al.|Allergy|2004Cited by 1.1k
Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled HypertensionLuke J. Laffin, Larkin T. Wadsworth, James M. Luther et al.|JAMA|2023Cited by 187
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M. Arabi, Anthony Gordon, Lennie Derde et al.|Intensive Care Medicine|2021Cited by 100
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trialsFleur L. Meulmeester, Simon Couillard, Samuel Mailhot-Larouche et al.|The Lancet Respiratory Medicine|2025Cited by 69
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trialLennie Derde, Ville Pettilä, Anthony Gordon et al.|Thorax|2025Cited by 12